These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 29860282)

  • 1. Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci.
    Scelsi MA; Khan RR; Lorenzi M; Christopher L; Greicius MD; Schott JM; Ourselin S; Altmann A
    Brain; 2018 Jul; 141(7):2167-2180. PubMed ID: 29860282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer's disease and implicate its dynamic role in disease progression.
    Wang Q; Chen Y; Readhead B; Chen K; Su Y; Reiman EM; Dudley JT
    Clin Epigenetics; 2020 Dec; 12(1):189. PubMed ID: 33298155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Novel Genes Associated with Cortical Thickness in Alzheimer's Disease: Systems Biology Approach to Neuroimaging Endophenotype.
    Kim BH; Choi YH; Yang JJ; Kim S; Nho K; Lee JM;
    J Alzheimers Dis; 2020; 75(2):531-545. PubMed ID: 32310165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease.
    Potkin SG; Guffanti G; Lakatos A; Turner JA; Kruggel F; Fallon JH; Saykin AJ; Orro A; Lupoli S; Salvi E; Weiner M; Macciardi F;
    PLoS One; 2009 Aug; 4(8):e6501. PubMed ID: 19668339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple loci influencing hippocampal degeneration identified by genome scan.
    Melville SA; Buros J; Parrado AR; Vardarajan B; Logue MW; Shen L; Risacher SL; Kim S; Jun G; DeCarli C; Lunetta KL; Baldwin CT; Saykin AJ; Farrer LA;
    Ann Neurol; 2012 Jul; 72(1):65-75. PubMed ID: 22745009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology.
    Ramanan VK; Lesnick TG; Przybelski SA; Heckman MG; Knopman DS; Graff-Radford J; Lowe VJ; Machulda MM; Mielke MM; Jack CR; Petersen RC; Ross OA; Vemuri P;
    Acta Neuropathol Commun; 2021 Mar; 9(1):48. PubMed ID: 33757599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
    Wang HF; Tan L; Hao XK; Jiang T; Tan MS; Liu Y; Zhang DQ; Yu JT;
    J Alzheimers Dis; 2015; 44(1):115-23. PubMed ID: 25182741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Multimodal Intermediate Phenotypes Between Genetic Risk Factors and Disease Status in Alzheimer's Disease.
    Hao X; Yao X; Yan J; Risacher SL; Saykin AJ; Zhang D; Shen L;
    Neuroinformatics; 2016 Oct; 14(4):439-52. PubMed ID: 27277494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
    Cao L; Wang HF; Tan L; Sun FR; Tan MS; Tan CC; Jiang T; Yu JT; Tan L;
    Oncotarget; 2016 Mar; 7(12):13319-27. PubMed ID: 26950278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.
    Deming Y; Li Z; Kapoor M; Harari O; Del-Aguila JL; Black K; Carrell D; Cai Y; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Huang KL; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Kim S; Saykin AJ; De Jager PL; Albert M; Moghekar A; O'Brien R; Riemenschneider M; Petersen RC; Blennow K; Zetterberg H; Minthon L; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Schellenberg G; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Peskind ER; Li G; Di Narzo AF; ; ; Kauwe JS; Goate AM; Cruchaga C
    Acta Neuropathol; 2017 May; 133(5):839-856. PubMed ID: 28247064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
    Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
    Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation and neuroimaging measures in Alzheimer disease.
    Biffi A; Anderson CD; Desikan RS; Sabuncu M; Cortellini L; Schmansky N; Salat D; Rosand J;
    Arch Neurol; 2010 Jun; 67(6):677-85. PubMed ID: 20558387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic interactions within inositol-related pathways are associated with longitudinal changes in ventricle size.
    Koran ME; Hohman TJ; Meda SA; Thornton-Wells TA
    J Alzheimers Dis; 2014; 38(1):145-54. PubMed ID: 24077433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying genetic markers enriched by brain imaging endophenotypes in Alzheimer's disease.
    Kim M; Wu R; Yao X; Saykin AJ; Moore JH; Shen L;
    BMC Med Genomics; 2022 Aug; 15(Suppl 2):168. PubMed ID: 35915443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease.
    Popescu SG; Whittington A; Gunn RN; Matthews PM; Glocker B; Sharp DJ; Cole JH;
    Hum Brain Mapp; 2020 Oct; 41(15):4406-4418. PubMed ID: 32643852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease.
    Ridge PG; Koop A; Maxwell TJ; Bailey MH; Swerdlow RH; Kauwe JS; Honea RA;
    PLoS One; 2013; 8(9):e74158. PubMed ID: 24040196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.